Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20387726 | 0.81 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1KDM4EHPGDLMNA | |
| SCHEMBL2323296 | 0.73 | KDM4E (0.43) | ALDH1A1KDM4ELMNAHTTMEN1 | |
| SCHEMBL15001201 | 0.72 | MERTK (0.39) | — | |
| SCHEMBL24449963 | 0.71 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1KDM4EHPGDLMNA | |
| SCHEMBL1855199 | 0.70 | HCAR3 (0.46) | ALDH1A1L3MBTL1KDM4EHPGDLMNA | |
| SCHEMBL15001195 | 0.70 | ATR (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL15117618 | 0.70 | ATR (0.38) | KDM4ERAB9AMAPTTP53TSHR | |
| SCHEMBL15001193 | 0.70 | MAPK8 (0.39) | ALDH1A1L3MBTL1 | |
| SCHEMBL4797767 | 0.69 | HPGD (0.40) | ALDH1A1L3MBTL1KDM4EHPGDLMNA | |
| SCHEMBL20722638 | 0.69 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1KDM4EHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118488947-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131122-A1 | FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3990443-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-2373653-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | PDGFRB, PDGFRA, FGFR1 | ALDH1A1 2831/4885L3MBTL1 4097/4885KDM4E 2905/4885 |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | ALDH1A1 3840/4885L3MBTL1 3474/4885KDM4E 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.